Home » Newsletters » BioWorld

BioWorld

Sep. 27, 1996

View Archived Issues

ANOTHER THREAT TO PATENTABILITY OF GENE THERAPY THWARTED

CLARIFICATIONS

GENZYME'S FIRST CARTICEL DATA POSITIVE GENZYME, DIACRIN FORM JOINT

VIROPHARMA FILES IPO TO FUND WORK ON RNA VIRUSES

OTHER NEWS TO NOTE

BIOCRYST PHARMACEUTICALS COMPLETES $20M OFFERING

HIV SUPPRESSION TRACED TO SHORT DELETION IN GENE CRUCIAL TO VIRAL

PHASE III DATA POSITIVE FOR MAGAININ'S ANTI- INFECTIVE DRUG

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 17, 2024.
Second insulin receptor offers new therapeutic avenues
BioWorld Science
Investigators at the Helmholtz Institute have shown that inceptor, an inhibitor of the insulin signaling pathway, acted by binding insulin and targeting it for...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.